At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06169579Phase 1Enrolling by InvitationUpdate OverdueUpdated 19mo ago · Completion was 6mo agoA Single-arm, Non-randomized, Open-label, Dose-escalation and Dose-expansion, Multicenter Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles, as Well as Preliminary Efficacy, of ND-003 in Chinese Patients With Advanced Solid Tumors.
In Brief
A Phase 1 clinical trial evaluating ND-003 tablets for Advanced Solid Tumor. Currently enrolling by invitation, targeting 96 participants across 21 sites.
Signals
Detailed Summary
This study is done to test the safety and preliminary efficacy of drug ND-003 tablets in patients with solid tumors. ND-003 is a highly potent and selective small molecular inhibitor of NTRK (neurotrophic receptor tyrosine kinase) and RET (rearranged during transfection). The study also investigates how the drug is absorbed and processed in the human body.
Study Details
Timeline
Interventions
ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
ND-003 tablets will be administered orally over continuous 28-days cycles.
ND-003 tablets will be administered orally over continuous 28-days cycles.